BeOne Medicines (BEIGF) Raw Materials (2024 - 2026)

BeOne Medicines (BEIGF) has 3 years of Raw Materials data on file, last reported at $274.2 million in Q1 2026.

• Raw Materials for Q1 2026 came in at $274.2 million, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $274.2 million (changed N/A YoY), and the FY2025 annual result was $236.2 million, up 38.46% from the prior year.
• Raw Materials improved to $274.2 million in Q1 2026 per BEIGF's latest filing, from $236.2 million in the prior quarter.
• Over five years, Raw Materials peaked at $274.2 million in Q1 2026 and troughed at $170.6 million in Q4 2024.
• A 3-year average of $227.0 million and a median of $236.2 million in 2025 frame the typical range for Raw Materials.
• On a YoY basis, Raw Materials climbed as much as 38.46% in 2025 and fell as far as 38.46% in 2025.
• A 3-year view of Raw Materials shows it stood at $170.6 million in 2024, then soared by 38.46% to $236.2 million in 2025, then increased by 16.1% to $274.2 million in 2026.
• Business Quant data shows BEIGF's Raw Materials at $274.2 million in Q1 2026, $236.2 million in Q4 2025, and $170.6 million in Q4 2024.